The future of incretin-based therapy: novel avenues--novel targets.
about
Emerging Evidence for the Importance of Dietary Protein Source on Glucoregulatory Markers and Type 2 Diabetes: Different Effects of Dairy, Meat, Fish, Egg, and Plant Protein FoodsThe treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesGLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.Benefits of healthy adipose tissue in the treatment of diabetes.Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetesEffects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study.The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.Glucose homeostasis during short-term and prolonged exposure to high altitudes.Polymer-based delivery of glucagon-like Peptide-1 for the treatment of diabetes.Evolving insights regarding mechanisms for the inhibition of insulin release by norepinephrine and heterotrimeric G proteins.Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Inflammation-sleep interface in brain disease: TNF, insulin, orexinTherapeutic gene delivery using bioreducible polymers.Molecular Pharmacology of the Incretin Receptors.Dual factor delivery of CXCL12 and Exendin-4 for improved survival and function of encapsulated beta cells under hypoxic conditions.Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.Rate of Homologous Desensitization and Internalization of the GLP-1 Receptor.Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry.A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion.
P2860
Q26741760-BE233B64-19D7-483D-B0D4-492369447E60Q26744317-4852FCDC-32A9-4A92-8DE3-BA5854160DD8Q33745485-4B6B2B4A-8F04-469D-9F77-55D765548179Q34023537-1D9227D9-D365-45F7-8F12-2303FDCADF23Q34299654-5E9ECF2D-583C-4A9D-9488-B88BED784B67Q35122108-D9B2BC2F-85AB-4D09-9251-EF691003954CQ35239483-244852EA-70BF-450E-801F-ACAA231A91C6Q35441680-211E8953-C80B-4136-AAF0-75FF02092418Q36014423-C9F7292B-42BC-4751-82B1-0D338AB555B9Q36041923-01391633-4CC5-4342-BE3C-69F8B538BD4BQ36186706-6B864C17-AE9D-4DD2-8215-B6B1DB3B81CAQ37340223-BAB36A19-351A-46F5-902C-88419F3EADF5Q37714770-32B5D38C-DC54-4C01-A5B3-07277A97DD27Q38157750-D6F5339A-5F63-4992-8AD0-2FF3C30D1A98Q38537930-8CF3F584-B9FE-4A7B-880E-88CDA7341606Q39189393-012B427C-1BC5-478D-861E-7F9F93550CABQ39198588-3129FB68-E3BF-4C8B-9D65-B204CE4915E5Q42503660-348F8CCA-2548-4529-BE7E-A7765E799C27Q43085677-B156BC17-FBEA-4E1F-A7B4-67E00B6F1B4EQ51348627-9687D306-F3D9-45FA-87A8-07BFF0FEC824Q51685119-20FEF9F1-3A66-4AC5-AB37-0AC147C06198
P2860
The future of incretin-based therapy: novel avenues--novel targets.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The future of incretin-based therapy: novel avenues--novel targets.
@en
The future of incretin-based therapy: novel avenues--novel targets.
@nl
type
label
The future of incretin-based therapy: novel avenues--novel targets.
@en
The future of incretin-based therapy: novel avenues--novel targets.
@nl
prefLabel
The future of incretin-based therapy: novel avenues--novel targets.
@en
The future of incretin-based therapy: novel avenues--novel targets.
@nl
P2860
P1476
The future of incretin-based therapy: novel avenues--novel targets.
@en
P2093
P2860
P304
P356
10.1111/J.1463-1326.2011.01457.X
P478
13 Suppl 1
P577
2011-10-01T00:00:00Z